Annual Drug Patent Expirations for XARELTO
Xarelto is a drug marketed by Janssen Pharms and is included in two NDAs. It is available from four suppliers. There are five patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for XARELTO.
This drug has seventy-eight patent family members in forty-six countries.
The generic ingredient in XARELTO is rivaroxaban. Four suppliers are listed for this compound. Additional details are available on the rivaroxaban profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
